Efficacy, Durability, And Retreatment Outcomes Of Risankizumab In Moderate To Severe Plaque Psoriasis: Results From The Phase 3 Immhance Trial. Journal of Carcinogenesis, [S. l.], v. 15, n. 1, 2016. DOI: 10.64149/. Disponível em: https://carcinogenesis.com/index.php/JOC/article/view/1825. Acesso em: 17 mar. 2026.